Biotech news for Monday, July 13, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Moderna (MRNA) announced a deal with the European Commission to supply up to 24 million doses of its RSV vaccine, mRESVIA, to EU member states. This agreement provides a significant revenue opportunity and expands Moderna's commercial footprint in the respirat…
Moderna (MRNA) appointed Michael McDonnell, former CFO of Biogen (BIIB), to its Board of Directors and audit committee, effective July 8, 2026. The move brings deep financial expertise from the life sciences sector, but shares retreated from a 52-week high, po…
Fate Therapeutics (FATE) received FDA clearance to begin clinical trials for its CAR-T cell therapy FT839, driving shares higher. The IND approval allows the company to advance this candidate into human studies, a key milestone for its pipeline and potential v…
BridgeBio Pharma (BBIO) hit a 52-week high after AstraZeneca and Ionis Pharmaceuticals reported a late-stage trial failure for their ATTR-CM drug, eplontersen. The setback boosts competitive prospects for BridgeBio's acoramidis and rivals Pfizer's tafamidis an…
Forte Biosciences (FBRX) shares surged after reporting that its lead candidate, FB102, achieved statistically significant improvement in vitiligo symptoms by nine weeks in an early-stage trial. The positive data de-risks the program and could support further d…
AstraZeneca (AZN) shares fell nearly 10% after the Phase III CARDIO-TTRansform trial for Wainua (eplontersen) failed to meet its primary efficacy goal in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The miss with partner Ionis (IONS) raises uncerta…
Cue Biopharma (NASDAQ: CUE) has raised approximately $50 million in an oversubscribed private placement with institutional investors. The company will issue 1.42 million shares of common stock. This capital infusion provides a significant cash runway to advanc…
The White House is reviewing final candidates for FDA commissioner, including Heidi Overton and Dr. Jeffrey Vacirca. The decision could impact drug approval timelines and regulatory policies for major pharma companies like Pfizer and Merck.
Silo Pharma (SILO) announced a private placement expected to raise approximately $4 million through the issuance of common shares and warrants. The offering, priced at $6.452 per share, includes Series A-3 and A-4 warrants. Shares fell on the news, reflecting…
HHS Secretary Robert F. Kennedy Jr. intends to compile a list of injuries linked to COVID-19 vaccines to compensate those harmed or killed. This could impact Pfizer (PFE) and Moderna (MRNA) by increasing legal and financial liabilities, potentially affecting i…
Alector (ALEC) announced that GSK (GSK) terminated their neuroscience collaboration covering two experimental antibody drugs after both candidates faced clinical setbacks. Alector shares dropped 13% in extended trading, while GSK shares eased 1.5%. The termina…
This week, PNC Financial and CF Industries announced dividend increases, while Costco and Phillips 66 declared their regular dividends. Investors should monitor these moves as they signal financial health and shareholder return policies, potentially impacting…